Profile
ACGN VRTX REGN VRNA ARGX ALNY
Company Name Aceragen, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $3.24M $122.53B $81.62B $72.68B $50.22B $43.35B
Employees 0.03K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO John C. Taylor Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
ACGN VRTX REGN VRNA ARGX ALNY
Quant Rating Score 4 4 1 4 3
Quant Rating Buy Buy Strong Sell Buy Neutral
Trading
ACGN VRTX REGN VRNA ARGX ALNY
Last Close $0.3849 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $0.38 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $0.38 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High 1.29 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 1.29 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
ACGN VRTX REGN VRNA ARGX ALNY
1 Month Return 0 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return 0 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 0 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 0 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 0 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 0 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACGN VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) - 9.76 % 3.92 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) - - 8.22 % - - -
Growth
ACGN VRTX REGN VRNA ARGX ALNY
Asset Growth 190 % 7.41 % 53.91 % 10.71 %
Gross Profit Growth - 1.16 % - 26.81 %
Revenue Growth - 0.99 % - 22.97 %
Revenue 3 Year 73.09 % 20.64 % -15.89 % 147.1 %
Revenue 5 Year 91.48 % 73.64 % - 775.72 %
Revenue 10 Year 494.85 % 285.02 % - 2487.4 %
EBIT Growth -100 % 9.09 % -131.37 % 24.59 %
Net Income Growth -123.81 % 2.09 % -224.78 % 36.82 %
Net Income 3 Yeari Growth Per Share 78.69 % 6.32 % -148.34 % 69.73 %
Net Income 5 Yeari Growth Per Share 87.42 % 31.91 % 25.82 % 73.13 %
Net Income 10 Yeari Growth Per Share 92.42 % 680.22 % -35.51 % 55.09 %
Operating Income Growth -0.52 % -7.46 % -133.02 % 37.31 %
Operating Cash Flow Growth (CFG) 0.41 % - -143.33 % -107.98 %
Operating 3 Year CFG 71.62 % -100 % -170.73 % 98.8 %
Operating 5 Year CFG 84.25 % -100 % 54.81 % 97.44 %
Operating 10 Year CFG 92.33 % -100 % 40.15 % 97.08 %
EPS Growth -121.42 % 5.31 % -214.81 % 38.07 %
EPS Diluted Growth 26.69 % 8.19 % -208.93 % 38.07 %
Book Value Per Share 17.5 % 32.88 % -22.82 % 129.75 %
Share Holder 3 Year Equity Growth Per Share 279.72 % 41.21 % 1.82 % -89.42 %
Share Holder 5 Year Equity Growth Per Share -87.16 % 191.63 % -24.45 % -96.01 %
Share Holder 10 Year Equity Growth Per Share -63.34 % 842.11 % -71.86 % -95.83 %
Dividend Per Share Growth - - - -
Dividend 3 Year Growth Per Share - - - -
Dividend 5 Year Growth Per Share - - - -
Dividend 10 Year Growth Per Share -100 % - - -
Debt Growth -26.12 % 0.06 % 139.05 % 110.16 %
Free Cash Flow Growth 0.41 % - -144.48 % -201.54 %
Updated On 31 Dec 2022 31 Dec 2025 31 Dec 2024 31 Dec 2024
Profitability
ACGN VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM - 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -23.1 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM -113.18 % 21.81 % 14.83 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM -34.91 % 19.59 % 10.3 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 78.71 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 106.69 % 111.4 % 146.19 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM - 34.06 % 24.95 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -4374.11 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM - 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM - 0.4 2.1 2.37 0.9 4.37
Inventory Turnover TTM - 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM - 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM - 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM -7.52 14.55 48.39 -0.85 5.67 2.02
Free Cash Flow Per Share TTM -7.52 13.06 39.66 -0.85 5.58 1.68
Cash Per Share TTM 369.9 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 34.71 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 89.76 % 81.96 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -4374.11 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM - 36.72 20 -995.27 128.45 195.85
Price To Operating Cash Flows Ratio TTM -0.06 32.86 16.23 -126.33 145.01 162.25
Price Cash Flow Ratio TTM -0.06 32.86 16.23 -126.33 145.01 162.25
Income Statement (TTM)
ACGN VRTX REGN VRNA ARGX ALNY
Revenue $0B $11.02B $14.34B $0.03B $2.19B $2.25B
Gross Profit $0B $9.49B $12.24B $0.03B $1.96B $1.92B
Gross Profit Ratio 100% 86.11% 85.35% 93.89% 89.62% 85.62%
EBITDA $-0.01B $0.49B $5.82B $-0.12B $0.11B $-0.18B
Net Income $-0.02B $-0.54B $4.5B $-0.14B $0.83B $-0.28B
EPS Diluted -7.17 -2.08 41.48 -1.73 12.78 -2.18
Balance Sheet (MRQ)
ACGN VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $1.66B $2.71B $0.12B $0.03B $2.59B
Total Liabilities $0.06B $6.12B $9.3B $0.27B $0.7B $4.17B
Total Equity $0.04B $16.41B $31.26B $0.2B $5.5B $0.07B
Total Investments $0B $6.65B $16.08B $0.02B $1.93B $1.73B
Total Debt $0B $1.75B $2.71B $0.12B $0.04B $2.74B
Total Assets $0.1B $22.53B $40.56B $0.47B $6.2B $4.24B
Cash Flow Statement (TTM)
ACGN VRTX REGN VRNA ARGX ALNY
Net Income $-0.02B $-0.54B $4.5B $-0.17B $0.83B $-0.28B
Inventory $0B $-0.52B $-0.28B $-0.01B $-0.1B $0.01B
Dividends Paid $0B $0B $-0.37B $0B $0B $0B
Operating Cash Flow $-0.02B $-0.49B $4.98B $-0.12B $-0.08B $-0.01B
Capital Expenditure $0B $-0.3B $-0.9B $-0B $-0.07B $-0.03B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.52
AARD Aardvark Therapeutics, Inc. Common Stock 12.65
ABCL AbCellera Biologics Inc. 3.16
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.13
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.4
ABPWW 0.0155
ABSI Absci Corporation 2.695
ABUS Arbutus Biopharma Corporation 3.84
ABVC ABVC BioPharma, Inc. 1.74
ABVX Abivax SA American Depositary Shares 117.67
ACAD ACADIA Pharmaceuticals Inc. 23.56
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 7.03
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.25
ACIU AC Immune SA 3.14
ACLX Arcellx, Inc. 68.03
ETFs With Exposure to ACGN
Ticker ETF Name Weight Percentage Price
VTI Vanguard Total Stock Market Index Fund 0 340.96
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 151.14
VXF Vanguard Extended Market Index Fund 0 217.96
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 165.43
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 165.44
VEMPX Vanguard Extended Market Index InstlPlus 0 408.25
Unlock